web analytics

Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer

4 September 2019 07:00 BST

Tagrisso approved in China as a 1st-line treatment

for EGFR-mutated non-small cell lung cancer

In the Phase III FLAURA trial, Tagrisso significantly increased the
time patients lived without disease progression versus the comparator

Tagrisso is the only medicine demonstrating statistically-significant
overall survival benefit in this setting

AstraZeneca today announced that it has received marketing authorisation from China’s National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-

Source: Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.